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Fibrolamellar carcinoma (FLC) is an uncommon malignant 
tumour of hepatocyte origin that differs from hepatocellular 
carcinoma (HCC) in aetiology, demographics, condition of 
the affected liver, tumour markers, and prognosis.1,2 In the 
past, FLC was termed eosinophilic hepatocellular carcinoma 
with lamellar fibrosis, hepatocellular carcinoma with polygo-
nal cell type and fibrous stroma, eosinophilic glassy cell hepa-
toma, and fibrolamellar oncocytic hepatocellular carcinoma.2 
First described by Edmondson in 1956, the distinct clinical 
and pathological features of FLC were not fully appreciated 
until 1980.2,3
If amenable, FLC, like most localised hepatic malig-
nancies, is best treated by complete surgical resection.2,4-6 
Positive prognostic factors include resectability, absence of 
lymph node metastases at presentation, normal serum liver 
enzymes, early clinical stage, and absence of vascular invasion 
or thrombosis.7,8 Regional lymphadenopathy and isolated 
metastases are not an obstacle to resection.2 A major nega-
tive prognostic factor is cirrhosis, which is associated with 
typical HCC in 90% of patients, but is rarely seen in FLC 
patients.1,7 Controversy exists whether, cirrhosis and resecta-
bility notwithstanding, FLC demonstrates a more favourable 
prognosis than typical HCC. In this study, we assessed the 
clinical outcome of patients with FLC who underwent liver 
resection at a tertiary centre in South Africa.
Patients and methods
We used the prospective liver resection database at Groote 
Schuur Hospital to identify patients who underwent sur-
gery for HCC between 1990 and 2008. We collected clinical 
information from the database, hospital notes, laboratory 
and pathology reports, and patient interviews. The following 
data were reviewed: patient demographics, imaging studies 
including ultrasound and computed tomography (CT), serol-
ogy, surgical procedures, pathological specimens, evidence 
of recurrence, and outcome. Follow-up was obtained by 
personal communication with patients, patients’ families, and 
referring physicians. We used the Couinaud nomenclature 
to define the extent of the surgical procedures: an extended 
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Background. Fibrolamellar carcinoma (FLC) is an uncommon 
malignant tumour of hepatocyte origin that differs from 
hepatocellular carcinoma (HCC) in aetiology, demographics, 
condition of the affected liver, and tumour markers. 
Controversy exists whether FLC demonstrates a more 
favourable prognosis than typical HCC. A review of existing 
literature reveals a dearth of FLC data from the African 
continent.
Methods. We utilised the prospective liver resection 
database at Groote Schuur Hospital to identify all patients 
who underwent surgery for FLC between 1990 and 2008.
Results. Seven patients (median age 21 years, range 
19 - 42, 5 men, 2 women) underwent surgery for FLC. No 
patient had underlying liver disease or an elevated alpha feto-
protein (AFP) at either initial presentation or recurrence. Six 
patients had a solitary tumour at diagnosis (mean largest 
diameter = 12cm), and underwent left hepatectomy (N=2), 
right hepatectomy (N=1), extended right hepatectomy (N=1), 
and segmentectomies (N=2). Three patients underwent 
a portal lymphadenectomy for regional lymphatic tumour 
involvement. One patient with advanced extrahepatic portal 
nodal metastasis was unresectable. No peri-operative 
deaths occurred. Recurrence occurred post resection in all 6 
patients. Median overall survival was 60 months, and overall 
5-year survival was 4 out of 7 (57%). Post-resection survival 
(N=6) was 61 months, with a 5-year survival rate of 4 out of 
6 (67%). The patient with unresectable disease survived 38 
months after tumour embolisation with Lipiodol.
Conclusion. Our series suggests that despite (i) a high 
resection rate of solitary lesions with clear tumour resection 
margins, and (ii) absence of underlying liver disease, FLC 
has a high recurrence rate with an ultimately poor clinical 
outcome. These findings concur with recent international 
experience of FLC.
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right hepatectomy is resection of segments 4 - 8; an extended 
left hepatectomy is resection of segments 2, 3, 4, 5 and 8; a 
right hepatectomy is resection of segments 5 - 8; and a left 
hepatectomy is resection of segments 2 - 4.9
Results
Over an 18-year period, 7 patients with FLC were identified. 
Median age was 21 years; 5 patients were men (Table I). 
None of the FLC patients had underlying liver disease (cir-
rhosis/HepB/HepC) or an elevated alpha-fetoprotein (AFP) 
at either initial presentation or recurrence (Table II). Our 
patients either presented with nonspecific abdominal pain or 
discomfort, or the tumours were discovered incidentally dur-
ing investigation of an unrelated medical condition. The aver-
age tumour size was 12 cm (range 4 - 17) (Fig. 1).
Table I. PaTIenTs and fIbrolamellar 
carcInoma characTerIsTIcs
Characteristics FLC (N=7)
median age, yrs (range) 21 (19 - 42)
male 5 (71%)




mean tumour size (cm) 12






median overall survival (mo.) 60
overall 5-year survival rate 4/7 (57%)
median post-op survival (mo.) 61
Post-resection 5-year survival rate 4/6 (67%)
FLC = fibrolamellar carcinoma; AFP = alpha-fetoprotein.
Fig. 1. Portal venous phase CT scan, showing a large, well-





















































































x (segs 2, 3), Pl 
– 1997
P h





















































































a; F = fem
ale; M
 = m
ale; AFP = alpha-fetoprotein; PH
x = partial hepatectom
y; R
 = right, L = left, PL = portal lym
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All 7 patients underwent laparotomy (Fig. 2). Two patients 
underwent a left hepatectomy, 1 had a right hepatectomy, 1 
had an extended right hepatectomy, and 2 patients had seg-
mentectomies which included segments 4, 5, and 6 in one, 
and segments 2 and 3 in the other (Table II). In addition 
to the liver resection, 3 patients underwent a portal lym-
phadenectomy for regional lymphatic tumour involvement 
(Table II). All patients developed recurrence post resection. 
One patient (patient 2, Table II) had a repeat liver resection 
and a retroperitoneal and coeliac axis lymphadenectomy 
45 months after the initial resection and lymphadenectomy. 
There were no peri-operative deaths. One patient who had 
extensive extraheptic portal nodal metastasis and ascites was 
irresectable. He underwent selective hepatic artery tumour 
embolisation with lipiodolised doxorubicin 10 days after 
laparotomy, and again 3 months later. 
FLC was confirmed histologically in all 7 patients. All 
resection margins were clear. Malignant vascular invasion was 
documented in 2 cases, and lymphatic involvement in 4 cases 
(Fig. 3). Histological analysis of all 7 specimens showed the 
distinctive histopathological features of FLC, which included 
large, polygonal, well-differentiated, eosinophilic cells with 
vesicular nuclei, prominent nucleoli and granular cytoplasm. 
In each specimen, the cells were arranged in sheets, cords, 
nests or trabeculae, surrounded and separated by distinct 
parallel lamellae of fibrous tissue (Fig. 4).
Median follow-up from date of operation was 61 months 
(range 7 - 69). The median overall survival of the 7 patients 
was 60 months. Following curative resection, median sur-
vival was 61 months, with a 5-year survival rate of 67%. The 
patient with irresectable disease survived 38 months after 
tumour embolisation with Lipiodol.
Discussion
While HCC is one of the most common malignancies glob-
ally, resulting in over one million deaths annually, FLC is 
rare, with an age-adjusted incidence rate of 0.02/100 000 
compared with 1.9/100 000 for HCC.10 FLC occurs world-
wide, and accounts for 0.85% of primary hepatic malignan-
cies in the West; unlike typical HCC, it is thought to be more 
prevalent in the USA and Europe than in Africa and Asia.2,10 
There are no associations with cirrhosis, hepatotoxins, α1-
antitrypsin deficiency and haemochromatosis, and fewer than 
10% of patients show evidence of hepatitis B and C viral 
infection.1,2,11 FLC most frequently presents in adolescents 
and young adults (mean age 23 years) in non-cirrhotic livers 
with no prior liver disease,2-4,11,12 and accounts for 13 - 22% 
of HCC in younger patients.10,13 Over 90% of cases occur 
in patients <35 years old, with <5% occurring in patients 
>50.1,2 Typical HCC affects males predominantly, but FLC 
affects both sexes equally.1,2,10 Our series demonstrated a 
male predominance, with a median age of 21 years at the 
time of diagnosis. About 10% of FLC patients show a mildly 
elevated serum AFP (often <200 ng/ml), in contrast with 
HCC patients, who frequently show elevated levels.2,11,12 
None of our patients had a raised serum AFP at either time 
of diagnosis or recurrence.
The macroscopic and microscopic appearance of FLC 
is distinctive. Grossly, FLC occurs as a large, single, non-
encapsulated, lobulated mass, ranging in size from 5 - 25 cm, 
and sharply demarcated from normal liver parenchyma (Fig. 
3).2,4,5 Eighty to 90% of cases demonstrate a solitary mass 
– as in all the patients in our series – but the tumour may also 
appear with small peripheral satellite lesions, as a bilobed 
mass or, rarely, as diffuse multifocal masses.2,12 Some publi-
cations have reported that both hepatic lobes were equally 
affected,1 while others contended that the left lobe was pre-
dominantly involved.2 Three of our patients had left-sided 
tumours, and a fourth patient had a central tumour involving 
both lobes. Fibrous tissue compartmentalises the tumour, 
often coalescing into a central stellate scar (20 - 60%).2,11,12 
Regional lymph node involvement is an indicator of poor 
prognosis.14 Distant metastases are seldom seen.1,2,6
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Fig. 2. Fibrolamellar carcinoma involving segments 4, 5 and 6.
Fig. 3a. A 140×85×130 mm fibrolamellar carcinoma replac-
ing the right hepatic lobe (patient 6, Table II).
Fig. 3b. Resected 11 cm lymph node containing tumour 
metastases.
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Controversy surrounds the question of whether, cirrho-
sis notwithstanding, FLC demonstrates more favourable 
biological behaviour than typical HCC. Some series have 
demonstrated a better survival rate in FLC patients com-
pared with HCC patients,3,10,12 which may be attributable 
to a preponderance of FLC patients with localised and 
resectable tumours. The median survival for unresected 
FLC is 12 months; the 5-year recurrence-free survival of 
patients with presumed successful resections is only 18%.14 
The largest population-based study (using the Surveillance, 
Epidemiology, and End Results (SEER) database) showed 
superior survival in FLC by comparing the FLC group 
(N=68) with the entire HCC group (N=7 896), but did 
not analyse patients with and without cirrhosis separately in 
multivariate analysis. El-Serag reported that 5-year survival 
for FLC patients – of 32% – was considerably better than 
the 5-year survival for HCC patients, of 6.8%. By separating 
the HCC group into those with underlying liver disease and 
those without, some studies have concluded that the bet-
ter survival in FLC patients might be due to the absence of 
cirrhosis rather than the unique clinicopathological features 
of the tumour.15 In a recent review of the clinicopathologi-
cal features of FLC, Torbenson7 concluded that the overall 
prognosis of FLC was better than that of typical HCC, 
and similar to that of HCC arising in non-cirrhotic livers. 
Other recent studies of children and young adults with FLC 
have also failed to show a more favourable prognosis.8,13 
Katzenstein et al. found no difference in prognosis, median 
survival, or incidence of surgical resectability at diagnosis 
between FLC and HCC in a cohort of 46 children, and con-
cluded that clinical staging, rather than histological subtype, 
had the most influence on outcome.13
Our overall 5-year survival rate was 57%, with a median 
survival of 60 months. In published case series, overall 5-year 
survival rates (in both resectable and unresectable cases) vary 
between 26% and 31%.8,10 Among our resectable FLC cases, 
5-year survival was 67%, with a median post-operative sur-
vival of 61 months. Following resection, overall 5-year sur-
vival rates increase to between 45% and 80%;14-17 the highest 
median survival reported is 112 months.14,16 In typical HCC 
patients, the prognosis is considerably worse: Stipa et al. 
reported a post-resection 5-year survival rate of 37% with 
median survival of 37 months; 13 patients with unresectable 
disease had a median survival of 12 months, and no patient 
survived beyond 5 years.
The recommended therapeutic approach for FLC is com-
plete surgical resection. Curative resection can prolong 
patient survival in cases of recurrent local disease, limited 
metastatic spread and/or recurrent lymphadenopathy.2,5,6,17 
In reported series, relapse rates are high, ranging from 64 - 
100%.14,16,17 In our series, recurrence occurred in all patients. 
The high likelihood of late tumour recurrence necessitates 
regular follow-up imaging studies in FLC patients.2,5,14 In 
inoperable cases, intra-arterial or systemic chemotherapy may 
render the tumour operable, allowing an attempt at curative 
resection.2 Orthotopic liver transplantation (OLT) and total 
hepatectomy may be considered for patients with nonresect-
able tumours confined to the liver;4,11 extra-hepatic disease, 
distant metastases, nodal involvement and vascular invasion 
are contraindications to liver transplantation. Limited afford-
ability and availability restrict the use of OLT, but newer 
innovative approaches may overcome these obstacles; these 
include adult live-related donors, split-liver techniques or the 
potential use of marginal donor organs.17
Conclusion
Our series suggests that despite (i) a high resection rate of 
solitary lesions with clear tumour resection margins, and (ii) 
absence of underlying liver disease, FLC has a high recur-
rence rate with an ultimately poor clinical outcome. These 
findings concur with recent international experience of FLC.
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Fig. 4. Histopathological features of fibrolamellar carcinoma 
demonstrating large, pleomorphic, intensely eosinophilic cells 
arranged in sheets separated by fibrous lamellae.
       
